Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2015

01-08-2015 | Original Article

Opioids have no negative effect on the survival time of patients with advanced lung cancer in an acute care hospital

Authors: Seigo Minami, Kosuke Fujimoto, Yoshitaka Ogata, Suguru Yamamoto, Kiyoshi Komuta

Published in: Supportive Care in Cancer | Issue 8/2015

Login to get access

Abstract

Purpose

The purpose of this study is to determine whether or not opioid administration influenced the survival time of patients with advanced lung cancer in an acute care hospital setting.

Methods

This was a single institutional and retrospective study. We reviewed patients with advanced lung cancer who had died from January 2008 to December 2013 at the Osaka Police Hospital. We compared survival times, calculated from the time of the last hospitalization or the last chemotherapy, between patients who had not used any opioids, those who had used a low dose of opioids (<60 mg/day), and those who had used a higher dose of opioids (≥60 mg/day).

Results

A total of 369 patients, of which 284 had received chemotherapy, were analyzed. Opioid users were generally younger than nonusers. There was no significant difference in survival time after the last hospitalization in terms of opioid dose at the last admission and mean daily opioid dose; there was also no significant difference in survival time after the last chemotherapy in terms of the mean daily opioid dose and the opioid dose at death. Univariate and multivariate Cox proportional hazard analysis regarding survival time after the last hospitalization or the last chemotherapy did not reveal any opioid-related variables as a significant predictive factor.

Conclusions

Opioids were found to have no negative influence on survival time even in an acute care hospital.
Appendix
Available only for authorised users
Literature
1.
Morita T, Tsunoda J, Inoue S, Chihara S (2000) Concerns of Japanese hospice inpatients about morphine therapy as a factor in pain management: a pilot study. J Palliat Care 16(4):54–58PubMed
2.
Reid CM, Gooberman-Hill R, Hanks GW (2008) Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol 19(1):44–48PubMedCrossRef
3.
Morita T, Miyashita M, Shibagaki M, Hirai K, Ashiya T, Ishihara T, Matsubara T, Miyoshi I, Nakaho T, Nakashima N, Onishi H, Ozawa T, Suenaga K, Tajima T, Akechi T, Uchitomi Y (2006) Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: a population-based survey in Japan. J Pain Symptom Manag 31(4):306–316CrossRef
4.
Azoulay D, Jacobs JM, Cialic R, Mor EE, Stessman J (2011) Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc 12(2):129–134PubMedCrossRef
5.
Bercovitch M, Adunsky A (2004) Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it? Cancer 101(6):1473–1477PubMedCrossRef
6.
Bercovitch M, Adunsky A (2006) High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20(4):33–39PubMedCrossRef
7.
Bercovitch M, Waller A, Adunsky A (1999) High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy. Cancer 86(5):871–877PubMedCrossRef
8.
Morita T, Tsunoda J, Inoue S, Chihara S (2001) Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manag 21(4):282–289CrossRef
9.
Portenoy RK, Sibirceva U, Smout R, Horn S, Connor S, Blum RH, Spence C, Fine PG (2006) Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manag 32(6):532–540CrossRef
10.
Thorns A, Sykes N (2000) Opioid use in last week of life and implications for end-of-life decision-making. Lancet 356(9227):398–399PubMedCrossRef
11.
Fohr SA (1998) The double effect of pain medication: separating myth from reality. J Palliat Med 1(4):315–328PubMedCrossRef
12.
Sykes N, Thorns A (2003) The use of opioids and sedatives at the end of life. Lancet Oncol 4(5):312–318PubMedCrossRef
13.
Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakaho T, Nakashima N, Shima Y, Matsubara T, Uchitomi Y (2005) Late referrals to specialized palliative care service in Japan. J Clin Oncol 23(12):2637–2644PubMedCrossRef
Metadata
Title
Opioids have no negative effect on the survival time of patients with advanced lung cancer in an acute care hospital
Authors
Seigo Minami
Kosuke Fujimoto
Yoshitaka Ogata
Suguru Yamamoto
Kiyoshi Komuta
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2592-6

Other articles of this Issue 8/2015

Supportive Care in Cancer 8/2015 Go to the issue

Review Article

The role of physical rehabilitation in stem cell transplantation patients

Original Article

Is there a role for survivorship care plans in advanced cancer?

Original Article

The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center

Letter to the editor

Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need

Original Article

Geriatric assessment as an aide to understanding falls in older adults with cancer

Erratum

Erratum to: Comparison of the acceptability and benefits of two mindfulness-based interventions in women with breast or gynecologic cancer: a pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits